Retatrutide is supplied by RS Bio Labs strictly as a laboratory research material for qualified scientific personnel. It is not approved, intended or authorised for human consumption, self-administration, diagnostic, therapeutic or veterinary use. All findings referenced here are from published preclinical or clinical-trial literature and do not constitute medical advice or establish safety in any unapproved setting.
The scientific lineage
To understand where Retatrutide came from, it helps to follow the thread of incretin science. The incretins are gut hormones — chiefly GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) — that are released after eating and help regulate insulin, appetite and glucose handling. Native GLP-1 was recognised in the 1980s and 1990s as a powerful regulator of metabolism, but it carried a fatal practical flaw for drug development: a half-life of only a couple of minutes, because the enzyme DPP-4 degrades it almost immediately.
The first major engineering problem, therefore, was longevity. Through the 2000s and 2010s researchers produced long-acting GLP-1 analogues — resistant to DPP-4 and, in the case of Semaglutide, conjugated to a fatty-acid chain so the molecule binds albumin and persists for days rather than minutes. Semaglutide's once-weekly schedule and ~15% weight reduction in pivotal trials proved that sustained GLP-1 receptor activation could be both practical and profoundly effective.
The next leap was to stop thinking about a single receptor. Eli Lilly engineered Tirzepatide, a single peptide that activates both the GIP and GLP-1 receptors — a "dual agonist" — reasoning that combining two complementary incretin pathways in one molecule would outperform either alone. Tirzepatide was approved by the FDA (as Mounjaro, and later Zepbound) in the early 2020s and delivered roughly 22.5% weight reduction, validating the multi-agonist thesis and setting the stage for the next step.
The conceptual leap: adding glucagon
Dual agonism worked by reducing energy intake more effectively. The idea behind Retatrutide was to also raise energy expenditure — the other side of the energy-balance equation. That meant recruiting a third receptor: the glucagon receptor (GCGR), whose activation is associated in research models with increased resting energy expenditure and hepatic lipid mobilisation. Bolting a glucagon-receptor arm onto the existing GIP/GLP-1 framework produced a tri-agonist design — a single engineered peptide hitting three receptors at once — which became Retatrutide, carrying the developer code LY3437943.
Preclinical rationale
The scientific appeal of a unimolecular multi-agonist is not only pharmacological but practical. Combining three separate drugs — one for each receptor — would mean three pharmacokinetic profiles, three dose titrations and a much harder safety and manufacturing picture. Engineering a single molecule that balances GIP, GLP-1 and glucagon activity in a fixed, deliberately tuned ratio sidesteps that complexity: one peptide, one pharmacokinetic profile, one schedule. Preclinical models supported the premise that a carefully weighted tri-agonist could lower food intake while increasing energy expenditure, without the glucagon arm driving unwanted increases in blood glucose — the key concern with glucagon-receptor activation.
Phase 1: first-in-human studies
Retatrutide entered first-in-human Phase 1 testing in the early 2020s (around 2021–2022). These early studies did what Phase 1 work is designed to do: establish basic tolerability, characterise the pharmacokinetics, and confirm the dosing rationale. They supported an acceptable tolerability profile at the doses studied and confirmed a half-life of roughly six days — the fatty-acid-conjugated, albumin-binding design working as intended and pointing to a once-weekly research schedule. With the pharmacology confirmed, the programme moved into efficacy testing.
2023: the TRIUMPH-1 landmark
The moment that put Retatrutide on the map came in 2023, when the Phase 2 TRIUMPH-1 results were published in the New England Journal of Medicine (Jastreboff et al.). In adults with obesity, the highest dose produced a mean body-weight reduction of approximately 24.2% — the largest effect reported for any incretin-class compound at that point, and a genuine headline moment for the field. Just as strikingly, the dose-response curve had not plateaued by the end of the study, suggesting the ceiling had not yet been reached. Overnight, the triple-agonist mechanism moved from an interesting hypothesis to the frontier of metabolic research.
Semaglutide (GLP-1) had delivered ~15% and Tirzepatide (GIP/GLP-1) ~22.5% in their pivotal trials. Retatrutide's ~24.2% at Phase 2 — still climbing — was the data point that established the tri-agonist as the next step in the incretin lineage.
Expansion and the Phase 3 TRIUMPH programme
On the strength of the Phase 2 data, development broadened. Alongside obesity, Retatrutide was studied in MASH (metabolic dysfunction-associated steatohepatitis), where Phase 2 work reported substantial reductions in liver-fat content, and in type-2 diabetes, where the compound's glucose-handling effects were of direct interest. From 2023 onward the compound advanced into the large Phase 3 TRIUMPH programme — the pivotal trials that a compound must clear to seek approval — including studies designed to assess cardiovascular outcomes, now a standard expectation for metabolic therapies.
| Year | Milestone |
|---|---|
| 1990s–2010s | Incretin foundations — native GLP-1's short half-life problem solved by long-acting analogues (e.g. Semaglutide). |
| Early 2020s | Tirzepatide, Eli Lilly's dual GIP/GLP-1 agonist, FDA-approved (Mounjaro/Zepbound) — the multi-agonist thesis validated. |
| ~2021–2022 | Retatrutide (LY3437943) first-in-human Phase 1 — tolerability, pharmacokinetics and the ~6-day half-life confirmed. |
| 2023 | Phase 2 TRIUMPH-1 published in NEJM — ~24.2% mean weight reduction, a headline moment for the field. |
| 2023 onward | Expansion into MASH and type-2-diabetes programmes; move into the Phase 3 TRIUMPH programme, including cardiovascular outcomes. |
| 2026 | Remains investigational — awaiting Phase 3 readouts and any regulatory decision. Not approved. |
Where it stands in 2026
As of 2026, Retatrutide is still an investigational compound. It has not been approved by the MHRA, FDA or any other regulator for any use, and it is not available as a medicine — the Phase 3 TRIUMPH programme is the gate it must clear before any approval decision could follow. Everything in this history is drawn from published clinical-trial and preclinical literature and is provided as a scientific reference only. For the underlying mechanism see What Is Retatrutide?, and for a consolidated view of the published data see the Retatrutide research summary. Products sold by RS Bio Labs are research reagents for in vitro laboratory work and are not for human use.